<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02473939</url>
  </required_header>
  <id_info>
    <org_study_id>VR942/1/001</org_study_id>
    <nct_id>NCT02473939</nct_id>
  </id_info>
  <brief_title>An Evaluation of VR942 in Healthy Volunteers and Patients With Mild Asthma</brief_title>
  <official_title>A Randomised, Double-blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single Inhaled Doses of VR942 in Healthy Subjects and Repeated Doses in Mild Asthmatics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vectura Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Vectura Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to Evaluate the safety, tolerability, pharmacodynamics and
      pharmacokinetics of single inhaled doses of VR942 in healthy subjects (part 1) and repeated
      doses in mild asthmatics (part 2).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events as a measure of the safety and tolerability of single doses of VR942 in healthy subjects and repeated doses of VR942 in mild asthmatics</measure>
    <time_frame>28 days</time_frame>
    <description>o Vital signs, physical examinations, any AEs or adverse device effects, laboratory tests, spirometry, and ECG variables</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The pharmacodynamics of repeat doses of VR942 in mild asthmatics</measure>
    <time_frame>28 days</time_frame>
    <description>o Change in biomarker levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The pharmacokinetic profile of single (Part 1) and repeated doses (part 2) of VR942 (time frame 4 and 14 days for Part 1 &amp; 2 respectively):</measure>
    <time_frame>4 and 14 days for Part 1 and 2 respectively</time_frame>
    <description>Part 1:
Cmax, tmax, t½, AUC0-t, AUC0-∞ and Kel
Part 2:
Cmax, tmax, and AUC0-τ (post-dose on Day 1) Ctrough on Days 2, 9 and 10 Cmax, tmax, t½, AUC0-t, AUC0-τ, Kel (post-dose on Day 10) Accumulation ratio Racc (Cmax on Day 10/Cmax on Day 1), (AUC0-τ on Day 10/AUC0-τ on Day 1) and (Cmin on Day 10/Cmin on Day 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of used blisters and inhalers that do not meet the performance characteristics of the device intended by the manufacturer</measure>
    <time_frame>28 days</time_frame>
    <description>o Examination of a sample of used blisters and inhalers will be conducted</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">85</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>VR942 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VR942 Dose 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VR942 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VR942 Dose 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VR942 Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VR942 Dose 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VR942 Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VR942 Dose 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VR942 Dose 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VR942 Dose 5</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VR942 delivered via a Vectura Dry Powder Inhaler</intervention_name>
    <arm_group_label>VR942 Dose 1</arm_group_label>
    <arm_group_label>VR942 Dose 2</arm_group_label>
    <arm_group_label>VR942 Dose 3</arm_group_label>
    <arm_group_label>VR942 Dose 4</arm_group_label>
    <arm_group_label>VR942 Dose 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo delivered via a Vectura Dry Powder Inhaler</intervention_name>
    <arm_group_label>VR942 Dose 1</arm_group_label>
    <arm_group_label>VR942 Dose 2</arm_group_label>
    <arm_group_label>VR942 Dose 3</arm_group_label>
    <arm_group_label>VR942 Dose 4</arm_group_label>
    <arm_group_label>VR942 Dose 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for Part I &amp; 2:

          -  Male or female subject.

          -  Female subjects of non-childbearing potential

          -  Weigh at least 50 kg, and body mass index 18.0-31.0

          -  Peak inspiratory flow (PIF) of at least 60 L/min for at least 2 sec

          -  Forced expiratory volume in 1 sec (FEV1)/forced vital capacity (FVC) ratio of at least
             0.7 at the screening visit

          -  Willingness to give written consent to participate after reading the information and
             consent form

          -  Willingness to give written consent to have data entered into The Over volunteering
             Prevention System.

          -  Additional inclusion criteria for Part 1:

          -  Healthy subjects with FEV1 and FVC of at least 80% of the predicted value at the
             screening visit

          -  Additional inclusion criteria for Part 2:

          -  Patients with documented clinical history of mild bronchial asthma (mild as defined by
             the GINA guidelines1) for at least 6 months before the screening visit

          -  Patient FEV1 and FVC of at least 70% of the predicted value at the screening visit

        Exclusion Criteria for Part 1 &amp; 2:

          -  Clinically relevant abnormal history, physical findings, ECG, or laboratory values at
             the pre-trial screening assessment

          -  Presence of acute or chronic illness or history of chronic illness sufficient to
             invalidate the subject's participation in the trial or make it unnecessarily hazardous
             (excluding mild asthma in Part 2)

          -  Impaired endocrine, thyroid, hepatic, respiratory (excluding mild asthma in Part 2) or
             renal function, diabetes mellitus, coronary heart disease, cancer, or history of any
             psychotic mental illness

          -  Respiratory tract infection within 4 weeks before the screening visit

          -  History of surgery or medical intervention, or planned surgery or medical intervention

          -  Presence or history of severe adverse reaction to any drug, or sensitivity to
             components of the trial medication

          -  Use of a prescription or over-the-counter medicine, with the exception of
             acetaminophen (paracetamol), during the 7 days before the first dose of trial
             medication. For Part 2 only, inhaled short-acting ß2 agonists, and ICS (stable dose
             with at least 2 weeks documented use of ≥80% compliance before screening and Day -1)
             are permitted

          -  Participation in another clinical trial of a new chemical entity, new device, or a
             prescription medicine within the 3 months before dosing, or participation within 5
             half-lives of receiving an experimental drug (whichever is longer)

          -  Presence or history of drug or alcohol abuse

          -  Evidence of drug abuse on urine testing, or a positive test for alcohol

          -  Current smoker; or ex-smokers who (a) gave up less than 1 year ago, or (b) who have a
             history of more than 10 pack-years

          -  Blood pressure and heart rate at the screening examination outside the ranges 90-140
             mm Hg systolic, 40-90 mm Hg diastolic; heart rate 40-100 beats/min.

          -  Loss of more than 400 mL blood, eg as a blood donor, or donation of blood products,
             during the 3 months before the trial

          -  Positive test for hepatitis B, hepatitis C, or HIV

          -  Possibility that the subject will not cooperate with the requirements of the protocol,
             including effective use of the DPI

          -  Additional exclusion criteria for Part 2:

          -  Life-threatening asthmatic episode in the past

          -  Asthmatic episode or respiratory tract infection requiring steroid treatment in the
             past 3 months

          -  Use of the following medicines within the specified time before screening:

               -  Long-acting ß2 agonists; At any time before screening

               -  Anti IgE therapy; 6 months

               -  Inhaled corticosteroids (&gt;500 µg per day of beclometasone dipropionate (BDP) or
                  equivalent); 8 weeks

               -  Oral or injectable steroids; 8 weeks

               -  Intranasal or topical steroids; 4 weeks

               -  Leukotriene antagonists; 2 weeks

               -  Xanthines (excluding caffeine), anticholinergics, cromoglycates; 1 week
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Vectura Study Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 29, 2015</study_first_submitted>
  <study_first_submitted_qc>June 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2015</study_first_posted>
  <last_update_submitted>December 19, 2016</last_update_submitted>
  <last_update_submitted_qc>December 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

